+AA
Fr
McMasterLogo_New-2017-300x165
Back
Clinician Article

SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.



  • Escobar C
  • Barrios V
  • Cosin J
  • Gamez Martinez JM
  • Huelmos Rodrigo AI
  • Ortiz Cortes C, et al.
Diabet Med. 2021 Mar;38(3):e14502. doi: 10.1111/dme.14502. Epub 2021 Jan 4. (Review)
PMID: 33368612
Read abstract
Disciplines
  • Family Medicine (FM)/General Practice (GP)
    Relevance - 6/7
    Newsworthiness - 7/7
  • General Internal Medicine-Primary Care(US)
    Relevance - 6/7
    Newsworthiness - 7/7
  • Endocrine
    Relevance - 6/7
    Newsworthiness - 5/7
  • Internal Medicine
    Relevance - 6/7
    Newsworthiness - 5/7

Abstract

OBJECTIVES: To assess the efficacy of glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose co-transporter 2 (SGLT2) inhibitors, administered without metformin on cardiovascular outcomes in type 2 diabetes patients.

METHODS: A systematic review was performed according to Cochrane's methodological standards. We included randomized clinical trials (RCTs) on adult type 2 diabetes patients, assessing the efficacy of SGLT2 inhibitors and GLP1-RAs compared to other glucose-lowering drugs and/or RCTs that presented data of a subgroup of type 2 diabetes patients without metformin use at baseline. The main outcome was the reduction of the risk of any major adverse cardiovascular events (MACE) reported individually or as a composite outcome.

RESULTS: Five RCTs including 50,725 type 2 diabetes patients, of whom 10,013 had not received metformin, were included in this meta-analysis. Three of these studies assessed the efficacy of GLP1-RAs and two of SGLT2 inhibitors. In patients without metformin at baseline, GLP1-RAs in comparison with placebo reduced the risk of MACE significantly by 20% (HR: 0.80; 95% CI: 0.71-0.89). SGLT2 inhibitors also significantly reduced the risk of MACE by 32% (HR: 0.68; 95% CI: 0.57-0.81).

CONCLUSIONS: SGLT2 inhibitors and GLP1-RAs provided without metformin at baseline may reduce the risk of MACE in comparison with placebo in type 2 diabetes patients at increased risk of cardiovascular events.


Clinical Comments

Endocrine

This is an interesting challenge to metformin's preeminence as the No.1 drug for type 2 diabetes. However, as the authors acknowledge, the data is too fragmentary at present.

Endocrine

This is important and provocative; the recommendations for the treatment of type II diabetes and the prevention of its cardiovascular consequences are challenged by SGLT2 inhibitors and GLP-1 receptor agonists. This meta-analysis based on data collected in >50,000 patients supports the promising expectations of the novel glucose-lowering therapies.

Internal Medicine

This study provides compelling evidence for the clinical benefit of SGLT-2 inhibitors and GLP-1 agonist in select population of patients with DM2T who are not receiving concomitant metformin therapy, a preferred initial pharmacological agent for DM2T in accordance with current ADA statement.

Register for free access to all Professional content

Register
Want the latest in aging research? Sign up for our email alerts.
Subscribe

Support for the Portal is largely provided by the Labarge Optimal Aging Initiative. AGE-WELL is a contributing partner. Help us to continue to provide direct and easy access to evidence-based information on health and social conditions to help you stay healthy, active and engaged as you grow older. Donate Today.

© 2012 - 2020 McMaster University | 1280 Main Street West | Hamilton, Ontario L8S4L8 | +1 905-525-9140 | Terms Of Use